You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
RegCell secures $66 million of additional funding to bring Nobel-winning immune tolerance science to the clinic.
PRIVATESep 15, 2026•1 day ago
Amount Raised
$66 Million
Round Type
Venture - Series Unknown
OsakaBiotechnologyTherapeutics
Description
RegCell has secured $66 million of additional funding aimed at advancing their Nobel-winning immune tolerance science. This funding will be crucial in bringing their innovative solutions to the clinic. The investment demonstrates confidence in RegCell's capabilities and future potential. The company is poised to make significant advancements in the field of immunology.
Company Information
Company
RegCell
Location
Osaka, Osaka Prefecture, Japan
About
Based on the discovery by our Founder, Professor Shimon Sakaguchi, we are developing stable, functional-induced Tregs that are antigen-specific (S/F-iTregs). Our S/F-iTregs address the limitations of earlier attempts to create therapeutic Tregs and competitive advantages over CAR-Treg approaches.
Don't miss RegCell's next move
Get an email the moment RegCell raises, hires an exec, or expands, usually minutes after it happens.
OsakaBiotechnologyTherapeutics